Ocugen Continues Uptick

Ocugen, Inc. (OCGN) shares are rising more than 9 percent on Monday morning continuing an uptrend since it submitted NDA for Phase 3 Clinical trial of its COVID-19 vaccine candidate COVAXIN (BBV152) on October 26. There were no corporate announcements on the day to impact the stock movement.

Currently, shares are at $12.94, up 9.29 percent from the previous close of $11.84 on a volume of 25,343,892. For the 52-week period, the shares have traded in a range of $0.25-$18.77 on average volume of 21,861,639.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT